These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37642395)

  • 1. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
    Zhou Y; Wang FR; Wen FF; Li C; Ye TT
    Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
    Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
    Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Rigato M; Fadini GP; Avogaro A
    Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
    Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
    Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
    Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
    Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.
    Fu EL; D'Andrea E; Wexler DJ; Patorno E; Paik JM
    Clin J Am Soc Nephrol; 2023 May; 18(5):592-601. PubMed ID: 36827225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.